Deutsche Bank AG Purchases 32,789 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Deutsche Bank AG raised its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 37.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 120,547 shares of the company's stock after purchasing an additional 32,789 shares during the quarter. Deutsche Bank AG owned 0.25% of Axsome Therapeutics worth $10,199,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new stake in Axsome Therapeutics during the 4th quarter valued at about $9,894,000. Cetera Investment Advisers grew its stake in shares of Axsome Therapeutics by 19.5% in the fourth quarter. Cetera Investment Advisers now owns 7,109 shares of the company's stock worth $601,000 after acquiring an additional 1,160 shares during the period. Brevan Howard Capital Management LP grew its stake in shares of Axsome Therapeutics by 169.9% in the fourth quarter. Brevan Howard Capital Management LP now owns 38,748 shares of the company's stock worth $3,278,000 after acquiring an additional 24,393 shares during the period. Bridgefront Capital LLC bought a new stake in shares of Axsome Therapeutics in the fourth quarter worth approximately $893,000. Finally, BVF Inc. IL grew its stake in shares of Axsome Therapeutics by 32.7% in the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock worth $117,444,000 after acquiring an additional 342,064 shares during the period. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $107.53 on Friday. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $139.13. The company has a market capitalization of $5.29 billion, a P/E ratio of -17.95 and a beta of 0.46. The firm's 50 day simple moving average is $110.49 and its two-hundred day simple moving average is $105.08.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The business had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Research analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on AXSM shares. Bank of America lifted their price target on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. Jefferies Financial Group started coverage on shares of Axsome Therapeutics in a research note on Monday, April 7th. They issued a "buy" rating and a $200.00 price target for the company. Robert W. Baird lifted their price target on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 6th. Morgan Stanley lifted their price target on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $176.00 target price for the company. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Axsome Therapeutics presently has an average rating of "Buy" and a consensus target price of $172.14.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.